Yissum, the technology transfer company of the Hebrew University of Jerusalem, has granted a worldwide exclusive license to BioLineRx to develop and commercialize BL-5040, a new antihormone for the treatment of inflammatory diseases.
Prof. Arie Belldegrun, Yissum's guest speaker at Biomed 2008, is convinced that the 21st century will focus on Biotech and calls upon all Israeli scientists to join hands in forming a flourishing Israeli Biotech industry.
PharmAthene Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a U.S. Phase I clinical trial evaluating Protexia(R) for safety and tolerability in humans. Protexia(R) is based on the invention of Prof. Hermona Soreq of the Hebrew University's Faculty of Science.
Rarely a week goes by when tech transfer giant Yissum, which handles IP commercialization for the Hebrew University of Jerusalem, doesn't announce a new innovation from its research labs. This week the company -- which claims to generate $1 billion annually from licensed products -- offers two technologies in two separate disciplines.
Prof. Daphne Atlas was chosen for her breakthrough research for treatment of neurodegenerative diseases. Her invention of an orally-available small molecule was licensed by Yissum to Eucalyptus Ltd.
A rose by any other name really would smell as sweet, after scientists discovered how to genetically introduce its scent into other flowers such as petunias and carnations.
Yissum introduced today a novel method for real time, automatic, generic and robust
pattern matching. The novel algorithm, developed by Professor Michael Werman and Ofir Pele, both from the School of Computer Science and Engineering at the Hebrew University of Jerusalem, enables very rapid recognition of a particular pattern in a fraction of the time currently available.
Based on a technology invented by Prof. Simon Benita of the Hebrew University's School of Pharmacy, Novagali Pharma, a French Laboratory specialized in ophthalmology announced today it has secured €15 million in a new financing round with the participation of the historical Company investors.
Israeli-U.S. company Beeologics is taking rapid measures to bring to market a proprietary anti-viral agent that promises to alleviate the effects of the virus strongly associated with Colony Collapse Disorder (CCD), with full-scale FDA trials commencing next month.
Prof. Re'em Sari of the Racah Institute of Physics investigates planets in the solar system and beyond: how they form and how they evolve.
BMW AG’s 7 Series sedan will be the first car to use a single computer chip-based camera to perform three functions: automatic headlight dimming, lane-departure warning and
automated traffic sign recognition.
The Israeli Biotechnology industry is mastered by women
Israel's research institutions, government, industries, and venture capital sector collaborate to nurture innovation. Like a good hockey team, they are playing a "shots on goal" game. They're not trying to pick the next Google (a bonanza for Stanford) or Gatorade (credit the University of Florida). They're building a pipeline to churn out hundreds of new ideas for businesses every year, knowing that only a few will ever fly in global markets.
Research that helps control errors in gene expression as a safer and more effective alternative to conventional drugs has won from Prof. Hermona Soreq, Dean of the Hebrew University Science Faculty one of this year's Kaye Innovation awards.
Nava Swersky Sofer aims to turn the academic wisdom of Hebrew University researchers the into money. This year revenues reached $50 million, and the future looks promising.
A material designed to prevent adhesions following surgery, patented by Yissum, has won for Hebrew University Prof. Daniel Cohn of the Casali Instititue of Applied Chemistry first prize in this year's Kaye Awards for Innovation. The awards were presented during the recent 71st meeting of the Hebrew University Board of Governors.
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR).
A novel device that enhances the diagnostic value of saliva has been produced by Hebrew University researchers. The disposable device clears whole saliva from its major protein constituent - alpha-amylase - to enable the detection of various low-abundance biomarkers.